Considerations for the Bioanalytical Part of Equivalence Studies of Biosimilar Nadroparin Calcium
According to current regulatory views, a comparative study of the pharmacodynamics (PD) of low molecular weight heparin (LMWH) products and confirmation of their equivalence require comparing three PD markers: the anti-Xa activity, the anti-IIa activity, and the tissue factor pathway inhibitor (TFPI...
Saved in:
Main Authors: | V. M. Kosman, M. V. Karlina, N. M. Faustova, E. A. Ezhova, I. G. Kotelnikova, V. G. Makarov, M. N. Makarova |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Federal State Budgetary Institution ‘Scientific Centre for Expert Evaluation of Medicinal Products’ of the Ministry of Health of the Russian Federation (FSBI ‘SCEEMP’)
2023-03-01
|
Series: | Регуляторные исследования и экспертиза лекарственных средств |
Subjects: | |
Online Access: | https://www.vedomostincesmp.ru/jour/article/view/406 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Comparative laboratory effectiveness of low molecular weight heparins in patients with acute coronary syndrome and no ST segment elevation
by: R. M. Linchak, et al.
Published: (2011-02-01) -
DEVELOPMENT, VALIDATION AND APPLICATION OF ANTI-Xa- AND ANTI-IIa-ENOXAPARINE SODIUM ASSAY
by: B. Yu. Margaeva, et al.
Published: (2019-01-01) -
Development and attestation of a standard sample of calcium nadroparin
by: A. V. Zykova, et al.
Published: (2024-06-01) -
Opportunities of using nadroparin calcium for prevention thrombotic complications at risk of coagulopathic bleeding
by: T. A. Sushko, et al.
Published: (2024-01-01) -
ANTITHROMBOTIC THERAPY IN CANCER PATIENTS
by: A. V. Vorobev, et al.
Published: (2016-06-01)